Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

Original reporting
Published Oct 14, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 11:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IVVD
Neutral
high confidence
Mentioned
$IVVD
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IVVDNeutralMed
01

Why it matters

The Phase 2 start is the first clinical evaluation for the indication, creating a new data‑driven price catalyst.

02

Market read

The announcement provides fresh, material information for IVVD shareholders and may influence biotech sector sentiment.

03

What to watch

Potential competition from other long‑COVID therapies and regulatory scrutiny of monoclonal antibodies.

Relevance 8/10Novelty 8/10Timing: today

Background

Invivyd (IVVD) is a Nasdaq‑listed biotech developing VYD2311, a monoclonal antibody with in‑vitro activity against SARS‑CoV‑2 variants.

Company-level read

Ticker impact

$IVVDNeutralHigh confidence
Context

Invivyd announced the initiation of a Phase 2 trial for its monoclonal antibody VYD2311 targeting Long COVID and Post‑Vaccination Syndrome.

Expected impact

potential upside as investors price in future efficacy data, tempered by trial‑risk uncertainty

Evidence & confidence

Phase 2 initiation is a primary disclosure for a biotech; markets typically react positively to new trial milestones, though the magnitude depends on data quality.

Market effects

Adds to the pipeline momentum in the biotech sector focused on COVID‑related therapeutics.

Limited to U.S. biotech investors; no broader regional effect.

Modest, as long‑COVID treatments are of global interest but the trial is early‑stage.

Counterpoint

The trial may face enrollment challenges and the market could discount the catalyst if prior COVID‑related biotech results have been disappointing.

Key entities

  • Invivyd, Inc.

    Biotech firm developing VYD2311 for long COVID.

  • VYD2311

    Monoclonal antibody targeting persistent SARS‑CoV‑2 spike protein.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.